The company was established in 2009, (formally, Rhonda L Bohn, LLC, renamed in 2016) in order to meet the new and growing needs for expert epidemiology consulting. Bohn Epidemiology’s success is a result of close collaboration with clients and the ability to provide insight and expertise to answer complex questions throughout the drug development process.
Bohn Epidemiology is a team of epidemiologists, statisticians, information specialists, data analysts and research assistants. Senior team members have doctorate degrees in epidemiology (or equivalent) with many having ten or more years of post-graduate experience.
Degrees in medicine, nursing, and pharmacy are also represented among senior staff. The company strives to match client needs with the most appropriate staff in relation to therapeutic area and methodologic expertise.
The company’s approach is to work with clients in an environment of transparency; team members work directly with clients to discuss their needs and provide guidance on the methodology needed to answer epidemiology questions related to signal detection, study design and execution, report content and preparation and ‘all matters epidemiology.’ The company’s strategic value resides in the team’s knowledge base, ability to provide quality deliverables, accessibility, and dedication to the company’s clients.
Dr. Bohn received her MPH from Yale University and ScD in Epidemiology from Harvard University. Prior to consulting, Rhonda worked in the private sector for pharmaceutical companies, consulting groups, and health insurers as well as spending ten years in academia where she was an Instructor in Medicine at the Brigham and Women’s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics.
Rhonda serves on Advisory Boards and Steering Committees for large-scale and multi-database studies representing clients and Medical Society Organizations. She has authored over 50 articles published in peer-reviewed journals and is a reviewer for many journals including Pharmacoepidemiology and Drug Safety, the Journal of Managed Care Pharmacy, Drug Safety, Thrombosis and Haemostasis, Pediatrics, and Haemophilia. She also served on the Editorial Board for Pharmacoepidemiology and Drug Safety from 2017-2018 and is an active member and Fellow of the International Society for Pharmacoepidemiology (ISPE) and served on its Board from 2014–2016.
Rhonda leads Bohn Epidemiology and is an active member of the research team. She ensures that the work delivered by the company exceeds client needs in terms of methodological and technical expertise as well as meeting timelines. In addition, Rhonda has strong relationships with academic groups and welcomes the opportunity to introduce her clients to both academic and industry experts.
Specialties include: Pharmacoepidemiology, Drug Safety Studies, Health Outcomes Research, Risk Management and Evaluation, Use of Large Administrative and EMR Databases for Epidemiologic Research, Corporate Strategy
Within these companies, Bohn Epidemiology works with stakeholders throughout these companies including epidemiology, statistics, health economics, outcomes research, pharmacovigilance, clinical affairs, drug development, commercial, and marketing. Many of the company’s clients have Centers of Excellence (COE) and Real World Evidence (RWE) organizations. These interdisciplinary teams engage Bohn Epidemiology to collaborate on large projects requiring both strategic and project-focused work.
Protocol design and implementation
Study operation and execution
Database expertise including multisite collaborations
Advisory board member (content and therapeutic area)
Rare diseases (hemophilia, cystic fibrosis, ALS, LSDs, others)
Advise on integration of epidemiology services
Business planning for epidemiology groups
Establishment of and direction of clinical and Methodology advisory boards
Initiate and participate in business collaborations and strategic partnerships
Safety surveillance/monitoring studies
Comparative effectiveness/ safety studies
Safety endpoint validation studies
Risk evaluation and mitigation studies
Burden of illness (incidence, prevalence)
Compliance and persistence
Rhonda and I have worked together as part of the Board of Directors for the International Society of Pharmacoepidemiology. Rhonda always brought very practical ideas to the Board meetings and, most importantly, she got things done. Her professional reputation combined with her outstanding inter-personal skills make Rhonda a node in the network within our field. “Everybody knows Rhonda.” She can communicate with colleagues in academia, industry and regulatory agencies. She has a broad understanding of drug development, from methods to policy. I have taken advantage of our collaborations by referring doctoral students to her for Real World experience. Several students in the Pharmacoepidemiology Program at the Harvard Chan School of Public Health have worked with her. Rhonda has been a great mentor for them both in terms of research applications and career orientation. With Rhonda they learned how to maintain high standards while delivering on time.
The high demand for epidemiology at Biogen and the internal resource constraints have created the need for outsourcing . Our highly skilled and experienced team of epidemiologists set a high bar for the capability of an outsourced partner. Bohn Epidemiology, under the leadership of Rhonda Bohn, has exactly and expertly fit our needs. Rhonda’s staff of epidemiologists consistently produce high quality reports, on time and ready for delivery to our internal stakeholders. Bohn Epidemiology is a collaborative, reliable, efficient organization of well-qualified epidemiologists and has become an indispensable resource for the Biogen Epidemiology function. It is a pleasure to work with Rhonda and her team.
We worked with Rhonda on a number of projects in a strategic, operational and regulatory capacity. Each and every time we found her to be a reliable and competent professional, who understands a sense of urgency and executes the highest quality deliverables.
Rhonda and I have collaborated together in a variety of settings. We conducted research together and published seminal papers on the health economics of hemophilia and the impact of home therapy. I have also seen and been involved in her speaking engagements in epidemiology as they relate to hemophilia. She is eloquent, precise and charming. She participated in international committees to devise guidelines in the field of hemophilia; her participation and concepts were right on target.
Without any question, the quality of Rhonda’s work has been first rate. Our company commissioned the development of a 44-page white paper to describe the incidence and prevalence of four in-line rare diseases. Rhonda conducted a comprehensive and targeted literature review that identified population-based epidemiology studies for each disease state and combined prevalence estimates from previous database studies. This work was extremely well received within the R&D organization and was an integral part of marketing and commercial assessments.
Rhonda and I have worked together from 2001 - 2014. It was one of the most enjoyable and productive collaborative working relationships I have had with a consultant. Rhonda helped me in many ways; she covered all therapeutic areas and worked independently (conducting literature reviews, designing studies, preparing study protocols and reports, monitoring studies, and to working on my behalf with third party experts and providing strategic advice). She also helped advise junior staff in various aspects regarding epidemiological approaches to study design. Regardless of the type of work I requested, she always completed the work on time and with the highest quality. I completely trust and rely on Rhonda as a consultant. I was frequently amazed at how little time she claimed she had used for each consulting project. Rhonda is surely one of the best working partners one can expect of a consultant.
Dr. Bohn has proven to be an invaluable expert to our Real World Evidence Team. She has contributed to the design and implementation of observational research. Also her strategic expertise has been indispensable in identifying and developing the necessary Real World Evidence Strategy for some of our key assets. Her significant methodologic and strategic expertise coupled with her impressive network have proven invaluable to the Epidemiology therapeutic heads.
I’ve been working with Rhonda for over 10 years, usually on highly complicated multi-site safety and effectiveness studies. She has the vision and skill to navigate complex research designs as well as institutional relationships to see a project through to successful completion.
I have been conducting pharmacoepidemiology and pharmacoeconomics research with Rhonda since 1991, when she joined our research group as one of its earliest epidemiologists. She played a pivotal role in developing the large observational datasets that we are still using today, and made many important methodological contributions to that work. We have gone on to publish a great number of papers together, demonstrating her versatility across many domains of the field. Our team continues to collaborate with her 25 years later and to benefit from her wealth of experience and collegiality.
Rhonda’s team has provided critical support to the Sage HEOR team for the past four years to help us better understand the epidemiology and burden of a range of CNS indications. The work provided by her team has always been thorough, robust, and well executed. The depth of knowledge regarding major depressive disorder, in particular, has been an exceptional resource.
Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21(12):1350-1358.